ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes... Show more
ATAI is expected to report earnings to fall 17.13% to -12 cents per share on August 18
Q2'25
Est.
$-0.12
Q1'25
Beat
by $0.01
Q4'24
Missed
by $0.09
Q3'24
Est.
$-0.16
Q2'24
Missed
by $0.20
The last earnings report on May 14 showed earnings per share of -15 cents, beating the estimate of -15 cents. With 11.75M shares outstanding, the current market capitalization sits at 571.12M.